Analysis of Data from Two Phase 3 Studies Shows DIFICIDÂ® Offered Faster Diarrheal Symptom Improvement than Oral Vancomycin in Patients with Cancer Being Treated for Clostridium difficile-Associated Diarrhea (CDAD)